This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tatsumi, T. Articles by Storkus, W. J. Search for Related Content PubMed PubMed Citation Articles by Tatsumi, T. Articles by Storkus, W. J.

Interleukin 18 Gene Transfer Expands the Repertoire of Antitumor Th1-type Immunity Elicited by Dendritic Cell-based Vaccines in Association with Enhanced Therapeutic Efficacy¹

Departments of Surgery [T. T., A. G., W. J. S.] and Molecular Genetics and Biochemistry [P. D. R., W. J. S.], University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261

Dendritic cells (DCs) are potent antigen-presenting cells that can prime and boost systemic antitumor immunity. Here, we have evaluated the ability of DCs transfected to secrete the potent Th1-biasing cytokine interleukin (IL)-18 to promote enhanced antitumor immunity in a mouse sarcoma model. DCs infected with a recombinant adenovirus encoding IL-18 (AdIL18DC) expressed higher levels of MHC and costimulatory molecules and were better stimulators than control DCs in mixed leukocyte reactions in vitro. Immunization of BALB/c mice bearing established day 7 CMS4 tumors with tumor peptide-pulsed control Ad5-transfected DCs or nontransduced DCs significantly inhibited the growth of established tumors but did not lead to complete regression of established tumors. Importantly, immunization with antigen-loaded AdIL18DC resulted in tumor rejection or further suppression of tumor growth when compared with controls. The repertoire of naturally presented tumor peptides recognized by splenocytes (as deduced in IFN- ELISA assays) from AdIL18DC-treated animals was far more diverse and of greater magnitude than that of all other groups, in association with improved therapeutic outcome. These results support the ability of IL-18 gene transfer to enhance the capacity of DCs to drive broadly reactive Th1-type therapeutic immunity prompted by single peptide epitope-based vaccines (i.e., epitope spreading).

This article has been cited by other articles:

				Q. Cao, W. Cai, G. Niu, L. He, and X. Chen Multimodality Imaging of IL-18-Binding Protein-Fc Therapy of Experimental Lung Metastasis Clin. Cancer Res., October 1, 2008; 14(19): 6137 - 6145. [Abstract] [Full Text] [PDF]

				B. Vasir, Z. Wu, K. Crawford, J. Rosenblatt, C. Zarwan, A. Bissonnette, D. Kufe, and D. Avigan Fusions of Dendritic Cells with Breast Carcinoma Stimulate the Expansion of Regulatory T Cells while Concomitant Exposure to IL-12, CpG Oligodeoxynucleotides, and Anti-CD3/CD28 Promotes the Expansion of Activated Tumor Reactive Cells J. Immunol., July 1, 2008; 181(1): 808 - 821. [Abstract] [Full Text] [PDF]

				M. Bachmann, C. Dragoi, M. A. Poleganov, J. Pfeilschifter, and H. Muhl Interleukin-18 directly activates T-bet expression and function via p38 mitogen-activated protein kinase and nuclear factor-{kappa}B in acute myeloid leukemia-derived predendritic KG-1 cells Mol. Cancer Ther., February 1, 2007; 6(2): 723 - 731. [Abstract] [Full Text] [PDF]

				F. Nishimura, J. E. Dusak, J. Eguchi, X. Zhu, A. Gambotto, W. J. Storkus, and H. Okada Adoptive Transfer of Type 1 CTL Mediates Effective Anti-Central Nervous System Tumor Response: Critical Roles of IFN-Inducible Protein-10. Cancer Res., April 15, 2006; 66(8): 4478 - 4487. [Abstract] [Full Text] [PDF]

				Q. Li, A. L. Carr, E. J. Donald, J. J. Skitzki, R. Okuyama, L. M. Stoolman, and A. E. Chang Synergistic Effects of IL-12 and IL-18 in Skewing Tumor-Reactive T-Cell Responses Towards a Type 1 Pattern Cancer Res., February 1, 2005; 65(3): 1063 - 1070. [Abstract] [Full Text] [PDF]

				T. Tatsumi, J. Huang, W. E. Gooding, A. Gambotto, P. D. Robbins, N. L. Vujanovic, S. M. Alber, S. C. Watkins, H. Okada, and W. J. Storkus Intratumoral Delivery of Dendritic Cells Engineered to Secrete Both Interleukin (IL)-12 and IL-18 Effectively Treats Local and Distant Disease in Association with Broadly Reactive Tc1-type Immunity Cancer Res., October 1, 2003; 63(19): 6378 - 6386. [Abstract] [Full Text] [PDF]

				C. N. Baxevanis, A. D. Gritzapis, and M. Papamichail In Vivo Antitumor Activity of NKT Cells Activated by the Combination of IL-12 and IL-18 J. Immunol., September 15, 2003; 171(6): 2953 - 2959. [Abstract] [Full Text] [PDF]